TCGA-BH-A0GY-01A-11R-A056-07
— · C
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- C
- subtype
- C
- overall_survival_months
- 31
GSVA pathway preview (0 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
8 twins match this tumor's tissue · 2 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | 6e639239-cdae-4412-880f-ef813a956ff7 | — | — | 0.847 |
| 2 | DRR168585 | — | — | 0.823 |
| 3 | SRR6013500 | — | cohortA1 | 0.812 |
| 4 | BS_850BAHH9 | ATRT | — | 0.811 |
| 5 | DRR168606 | — | — | 0.804 |
| 6 | BS_996ZS2A4 | ATRT | — | 0.804 |
| 7 | SRR6013499 | — | cohortA1 | 0.804 |
| 8 | 4c8b5d7c-d82b-4504-9b9e-3946ca14251e | — | — | 0.796 |
| 9 | SRR26320090 | — | — | 0.795 |
| 10 | SRR8613733 | — | C | 0.794 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 40 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| MYC_TARGETS_V2 | 0.410 | Idelalisib | — uncovered |
| MYC_TARGETS_V1 | 0.350 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.340 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.310 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.310 | Idelalisib | — uncovered |
| COMPLEMENT | 0.280 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.280 | Idelalisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.260 | Idelalisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.260 | Inavolisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.250 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.240 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.240 | Inavolisib | — uncovered |
| UV_RESPONSE_UP | 0.240 | Idelalisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.230 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.230 | Idelalisib | — uncovered |
| ANGIOGENESIS | 0.210 | Remibrutinib | — uncovered |
| ALLOGRAFT_REJECTION | 0.200 | Idelalisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.200 | Idelalisib | — uncovered |
| PROTEIN_SECRETION | 0.180 | Remibrutinib | — uncovered |
| APOPTOSIS | 0.170 | Idelalisib | — uncovered |